Treatable newborn and infant seizures due to inborn errors of metabolism

Area of Science:

• Biochemistry
• Neurology
• Genetics

Background:

• Approximately 25% of neonatal seizures originate from causes beyond birth asphyxia, ischemia, or intracranial bleeding.
• Primary genetic epileptic encephalopathies and inborn errors of metabolism represent significant, often severe, causes of neonatal seizures.
• Some metabolic causes of infant seizures are refractory to standard anti-epileptic drugs (AEDs) but responsive to specific metabolic interventions.

Purpose of the Study:

• To review inborn errors of metabolism presenting as newborn and infant seizures and epilepsy.
• To highlight the distinct treatment approaches, particularly cofactor therapy, for these specific metabolic conditions.
• To emphasize the importance of early recognition for improved seizure control and prevention of neurological sequelae.

Main Methods:

• Literature review of inborn errors of metabolism causing neonatal/infant seizures.
• Analysis of treatment strategies, focusing on cofactor-based therapies.
• Comparison with conventional epilepsy management protocols.

Main Results:

• Identified specific inborn errors of metabolism as treatable causes of neonatal seizures.
• Demonstrated that cofactor treatment can be highly effective where standard AEDs fail.
• Highlighted the potential for preventing neurological deterioration through timely diagnosis and targeted metabolic intervention.

Conclusions:

• Inborn errors of metabolism are an important, treatable differential diagnosis for neonatal seizures.
• Early identification and specific metabolic treatment, including cofactor therapy, are vital for optimal outcomes in affected infants.
• This contrasts sharply with the management of typical epileptic syndromes, necessitating a distinct diagnostic and therapeutic approach.